Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene

Luigi Gennari, Daniela Merlotti, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Selective estrogen receptor modulators (SERMs) represent a class with a growing number of compounds that act as either estrogen rec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luigi Gennari, Daniela Merlotti, Ranuccio Nuti
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	SERM – Lasofoxifene – Postmenopausal Osteoporosis – Fractures – Bone Density – Menopause Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/710260fdbd414cfe956d013b4a9c7646
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:710260fdbd414cfe956d013b4a9c7646
record_format	dspace
spelling	oai:doaj.org-article:710260fdbd414cfe956d013b4a9c76462021-12-02T07:28:51ZSelective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene1178-1998https://doaj.org/article/710260fdbd414cfe956d013b4a9c76462010-01-01T00:00:00Zhttps://www.dovepress.com/selective-estrogen-receptor-modulator-serm-for-the-treatment-of-osteop-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Luigi Gennari, Daniela Merlotti, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Selective estrogen receptor modulators (SERMs) represent a class with a growing number of compounds that act as either estrogen receptor agonists or antagonists in a tissuespecific manner. This article reviews lasofoxifene, a new-generation SERM that has completed phase III development for the prevention and treatment of osteoporosis in postmenopausal women. Consistent with preclinical observations, this new SERM demonstrated improved skeletal efficacy over raloxifene and at an oral dose of 0.5 mg/day was effective in the prevention of both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. At the same dosage, lasofoxifene treatment also reduced estrogen receptor-positive breast cancer risk and the occurrence of vaginal atrophy, but, like the other SERMs, was associated with hot flushes and an increased risk of venous thromboembolic events. With its increased efficacy on the prevention of nonvertebral fractures than current available SERMs and its positive effects on the vagina, this new compound may represent an alternative and cost-effective therapy for osteoporosis in postmenopausal women.Keywords: SERM, lasofoxifene, postmenopausal osteoporosis, fractures, bone density, menopauseLuigi GennariDaniela MerlottiRanuccio NutiDove Medical PressarticleSERM – Lasofoxifene – Postmenopausal Osteoporosis – Fractures – Bone Density – MenopauseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 19-29 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	SERM – Lasofoxifene – Postmenopausal Osteoporosis – Fractures – Bone Density – Menopause Geriatrics RC952-954.6
spellingShingle	SERM – Lasofoxifene – Postmenopausal Osteoporosis – Fractures – Bone Density – Menopause Geriatrics RC952-954.6 Luigi Gennari Daniela Merlotti Ranuccio Nuti Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
description	Luigi Gennari, Daniela Merlotti, Ranuccio NutiDepartment of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Siena, ItalyAbstract: Selective estrogen receptor modulators (SERMs) represent a class with a growing number of compounds that act as either estrogen receptor agonists or antagonists in a tissuespecific manner. This article reviews lasofoxifene, a new-generation SERM that has completed phase III development for the prevention and treatment of osteoporosis in postmenopausal women. Consistent with preclinical observations, this new SERM demonstrated improved skeletal efficacy over raloxifene and at an oral dose of 0.5 mg/day was effective in the prevention of both vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. At the same dosage, lasofoxifene treatment also reduced estrogen receptor-positive breast cancer risk and the occurrence of vaginal atrophy, but, like the other SERMs, was associated with hot flushes and an increased risk of venous thromboembolic events. With its increased efficacy on the prevention of nonvertebral fractures than current available SERMs and its positive effects on the vagina, this new compound may represent an alternative and cost-effective therapy for osteoporosis in postmenopausal women.Keywords: SERM, lasofoxifene, postmenopausal osteoporosis, fractures, bone density, menopause
format	article
author	Luigi Gennari Daniela Merlotti Ranuccio Nuti
author_facet	Luigi Gennari Daniela Merlotti Ranuccio Nuti
author_sort	Luigi Gennari
title	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
title_short	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
title_full	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
title_fullStr	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
title_full_unstemmed	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
title_sort	selective estrogen receptor modulator (serm) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/710260fdbd414cfe956d013b4a9c7646
work_keys_str_mv	AT luigigennari selectiveestrogenreceptormodulatorsermforthetreatmentofosteoporosisinpostmenopausalwomenfocusonlasofoxifene AT danielamerlotti selectiveestrogenreceptormodulatorsermforthetreatmentofosteoporosisinpostmenopausalwomenfocusonlasofoxifene AT ranuccionuti selectiveestrogenreceptormodulatorsermforthetreatmentofosteoporosisinpostmenopausalwomenfocusonlasofoxifene
_version_	1718399408227221504

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene

Ejemplares similares